These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1296 related articles for article (PubMed ID: 27251914)

  • 21. Alzheimer's disease: clinical evaluation and disease management--update.
    Richter RW
    J Okla State Med Assoc; 2004 Dec; 97(12):546-54; quiz 555-6. PubMed ID: 15732886
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
    O'Brien JT; Burns A;
    J Psychopharmacol; 2011 Aug; 25(8):997-1019. PubMed ID: 21088041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update on huperzine A as a treatment for Alzheimer's disease.
    Little JT; Walsh S; Aisen PS
    Expert Opin Investig Drugs; 2008 Feb; 17(2):209-15. PubMed ID: 18230054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets.
    Li W; Mak M; Jiang H; Wang Q; Pang Y; Chen K; Han Y
    Neurotherapeutics; 2009 Jan; 6(1):187-201. PubMed ID: 19110209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug therapy for Alzheimer's disease].
    Shoji M
    Brain Nerve; 2010 Jul; 62(7):777-85. PubMed ID: 20675882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination Drug Therapy for the Management of Alzheimer's Disease.
    Kabir MT; Uddin MS; Mamun AA; Jeandet P; Aleya L; Mansouri RA; Ashraf GM; Mathew B; Bin-Jumah MN; Abdel-Daim MM
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapeutic combinations for the treatment of Alzheimer's disease.
    Nagata T; Shinagawa S; Nakajima S; Noda Y; Mimura M
    Expert Opin Pharmacother; 2022 Apr; 23(6):727-737. PubMed ID: 35230200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
    Tayeb HO; Yang HD; Price BH; Tarazi FI
    Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease].
    Franke AG; Lieb K; Fellgiebel A
    Fortschr Neurol Psychiatr; 2009 Jun; 77(6):326-33. PubMed ID: 19504422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive symptoms of Alzheimer's disease: clinical management and prevention.
    Joe E; Ringman JM
    BMJ; 2019 Dec; 367():l6217. PubMed ID: 31810978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amyloid β-targeted metal complexes for potential applications in Alzheimer's disease.
    Liu H; Qu Y; Wang X
    Future Med Chem; 2018 Mar; 10(6):679-701. PubMed ID: 29400551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer's disease: a review of recent developments.
    Salawu FK; Umar JT; Olokoba AB
    Ann Afr Med; 2011; 10(2):73-9. PubMed ID: 21691010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acetylcholinesterase inhibitors: novel activities of old molecules.
    Racchi M; Mazzucchelli M; Porrello E; Lanni C; Govoni S
    Pharmacol Res; 2004 Oct; 50(4):441-51. PubMed ID: 15304241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
    Salomone S; Caraci F; Leggio GM; Fedotova J; Drago F
    Br J Clin Pharmacol; 2012 Apr; 73(4):504-17. PubMed ID: 22035455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
    Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
    Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.